New agents for the treatment of AML recent study findings.
Gore
Steven D
SD
D000227:Adenine Nucleotides / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001087:Arabinonucleosides / Q000627:therapeutic use; D001374:Azacitidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D002227:Carbazoles / Q000627:therapeutic use; D000077866:Clofarabine; D000077209:Decitabine; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D005663:Furans; D006801:Humans; D006834:Hydrazines / Q000627:therapeutic use; D007167:Immunotherapy; D000077269:Lenalidomide; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D015363:Quinolones / Q000627:therapeutic use; D019311:Staurosporine / Q000031:analogs & derivatives / Q000627:therapeutic use; D013449:Sulfonamides / Q000627:therapeutic use; D013792:Thalidomide / Q000031:analogs & derivatives / Q000627:therapeutic use
D000227:Adenine Nucleotides; D000970:Antineoplastic Agents; D001087:Arabinonucleosides; D002227:Carbazoles; D004791:Enzyme Inhibitors; D005663:Furans; D006834:Hydrazines; D015363:Quinolones; D013449:Sulfonamides; C483604:laromustine; D013792:Thalidomide; D000077866:Clofarabine; D000077209:Decitabine; C119379:lestaurtinib; D000077269:Lenalidomide; D019311:Staurosporine; C059539:midostaurin; D001374:Azacitidine; C402769:tipifarnib